Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis

References

• Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20(6):1048-56
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. Ovarian cancer survival statistics (online). 2011. Available from: http:/info,cancerresearchuk.org/cancerstats/types/ovary/survival
   Google Scholar
• Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007;18(3):875-85
   PubMed Web of Science ®Google Scholar
• Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008;19(6):1092-105
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16(6):1788-93
   PubMed Web of Science ®Google Scholar
• Phosphate binder use (national sample). US DOPPS Practice Monitor, October. 2013. Available from: www.dopps.org/DPM
   Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31(4):607-17
   PubMed Web of Science ®Google Scholar
• Block G, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67(3):1179-87
   PubMed Web of Science ®Google Scholar
• Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70(2):351-7
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5(3):519-30
   PubMed Web of Science ®Google Scholar
• Pohlmeier R, Vienken J. Phosphate removal and hemodialysis conditions. Kidney Int Suppl 2001;78:S190-4
   PubMedGoogle Scholar
• Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60(1):90-101
   PubMed Web of Science ®Google Scholar
• Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013;84(5):998-1008
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7(3):487-93
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bindren 92 - Public assessment report, 15 November 2012. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002377/human_med_001595.jsp&mid=WC0b01ac058001d124 [Last accessed 9 November 2013]
   Google Scholar
• Rosenbaum DP, Holmes-Farley SR, Mandeville WH, et al. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 1997;12:961-4
   PubMed Web of Science ®Google Scholar
• Kurihara S, Tsuruta Y and Akizawa T. Effect of COLESTILAN(colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplantation 2005;20:424-30
   PubMed Web of Science ®Google Scholar
• Locatelli F, Dimkovic N, Pontoriero G, et al. Effect of colestilan on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo controlled study. Nephrol Dial Transplant 2010;25:574-81
   PubMed Web of Science ®Google Scholar
• Locatelli F, Dimkovic N, Spasovski G. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant 2013;28(7):1874-88
   PubMed Web of Science ®Google Scholar
• Hertel JE, Nakajima S, Sano H, et al. Colestilan (COLESTILAN), a new calcium-free phosphate binder, is safe and effective in stage 5 CKD dialysis patients: phase 3, randomized, double-blind (DB), placebo (PBO)-controlled, multicenter study [abstract F-PO1862]. J Am Soc Nephrol 2010;21:538A
   Google Scholar
• Senatore F, Manning A, Nakajima S. A multi-centre, open-label, flexible dose, long-term safety study of colestilan in chronic kidney disease stage 5 subjects on dialysis with hyperphosphataemia. Nephrol Dial Transplant 2012;27(suppl 2):ii52-4
   Google Scholar
• Locatelli F, Spasovski G, Dimkovic N, et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transplant 2013;29(5):1061-73
   PubMedGoogle Scholar
• Wanner C, März A, Varushchanka A, et al. A randomized, controlled trial of colestilan versus simvastatin for treatment of dyslipidemia in hemodialysis patients. Clin Nephrol 2014;82(3):163-72
   PubMedGoogle Scholar
• Dellanna F, Spasovski G, Wanner C, et al. LDL-Cholesterol Lowering in Chronic Kidney Disease Stage V Dialysis Patients with Hyperphosphataemia: a Comparison of Colestilan (COL) and Sevelamer (SEV). Nephrol Dial Transplant 2014; abstrac
   PubMedGoogle Scholar
• Kondo K, Kadowaki T. Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study. Diabetes Obes Metab 2010;12:246-51
   PubMed Web of Science ®Google Scholar
• Staels B, Kuipers F. Bile acid sequestrants and the treatment of type-2 diabetes mellitus. Drugs 2007;67:1383-92
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance and diabetes by bile acid binding resin. Diabetes 2007;56:239-47
   PubMed Web of Science ®Google Scholar
• Duran-Sandoval D, Cariou B, Percevault F, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005;280:29971-9
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB. The ‘forgotten’ bile acid sequestrants: is now a good time to remember? Am J Ther 2007;14:567-80
   PubMed Web of Science ®Google Scholar
• Garg J, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis. Arthritis Rheum 2005;52:290-5
   PubMed Web of Science ®Google Scholar
• Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Internal Medicine 2009;48:415-20
   PubMed Web of Science ®Google Scholar
• Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 2011;6(10):2470-7
   PubMed Web of Science ®Google Scholar
• Feng S, Jiang L, Shi Y, et al. Uric acid levels and all-cause mortality in peritoneal dialysis patients. Kidney Blood Pressure Research 2013;37:181-9
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011;2:CD006023
   PubMedGoogle Scholar
• Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-52
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68(4):1815-24
   PubMed Web of Science ®Google Scholar
• Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20(8):1653-61
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics: bindRen 1 g film-coated tablets. Mitsubish, 8 August 2013. Available from: www.medicines.org/emc
   Google Scholar
• Summary of product characteristics: renvela 800 mg film coated tablets. Sanofi, December 2011. Available from: www.medicines.org/emc
   Google Scholar
• Manning A, Konig E, Tigat S, et al. Administration of a phosphate binder with food and drink: practical observations. European Dialysis and Transplantation Association 2014; [In press]
   Google Scholar
• Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009;75(9):890-7
   PubMed Web of Science ®Google Scholar
• Ketteler K, Wuthrich R, Floege J. Management of hyperphosphataemia in chronic kidney disease – challenges and solutions. Clin Kidney 2013;6:128-36
   PubMedGoogle Scholar
• Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39(4):695-701
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
   PubMed Web of Science ®Google Scholar
• Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009;20:381-7
   PubMed Web of Science ®Google Scholar
• Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009;20:397-404
   PubMed Web of Science ®Google Scholar
• Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15(7):1014-21
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438-41
   PubMed Web of Science ®Google Scholar
• London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18(9):1731-40
   PubMed Web of Science ®Google Scholar
• Verbeke F, Van Biesen W, Honkanen E; CORD Study Investigators. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011;6(1):153-9
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006;1(4):697-703
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
   PubMed Web of Science ®Google Scholar
• Hill KM, Martin BR, Wasney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013;83:959-66
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Chen H, et al. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Ren Fail 2014;36:1244-52
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Molony D, Bell C; INDEPENDENT Study Investigators. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013;62(4):771-8
   PubMed Web of Science ®Google Scholar
• Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61
   PubMed Web of Science ®Google Scholar